Early data shows Moderna’s COVID-19 vaccine is 95% effective
Pharmaceutical company Moderna on Monday claimed the coronavirus disease 2019 (COVID-19) it manufactured was 95% effective, based on interim data from a late-stage trial.
The US biotech company made the announcement a week after Pfizer Inc’s reported that it’s vaccine was also more than 90% effective.
Unlike Pfizer’s vaccine, Moderna’s experimental drug does not need ultra-cold storage, making it more accessible.
Moderna reported the results showing more than 300,000 participants were involved in the clinical trial, including people at high risk for severe COVID-19.
The vaccine also showed to have prevented severe COVID-19 cases when it was allotted in two shots 28 days apart.
However, short-lived muscle aches, redness, fever, and headaches were some of the side effects recorded to have occurred after the second dose, but were classified as mild or moderate.
The World Health Organization has recorded over 54.7 million cases of COVID-19, including 1.32 million deaths.